login
login
Image header Agence Europe
Europe Daily Bulletin No. 12979
Contents Publication in full By article 25 / 28
NEWS BRIEFS / Health

EMA recommends authorisation of Valneva’s Covid-19 vaccine

24/06/2022 (Agence Europe)The European Medicines Agency (EMA) recommended, on Thursday 23 June, a conditional marketing authorisation for the SARS-CoV-2 vaccine developed by the firm Valneva. This developed inactivated whole virus vaccine is the sixth vaccine recommended by the EMA. The vaccine is currently recommended for adults between the ages of 18 and 50. The EMA states that the vaccine dossier contains the results of an immunobridging trial. Placebo-controlled efficacy trials have previously been the gold standard for authorisation of SARS-CoV-2 vaccines, but the EMA considers that the trial was well designed and that there are sufficient authorised vaccines now to provide a comparison. The EMA states that it is also becoming difficult to recruit unvaccinated or patients who have not been exposed to SARS-CoV-2 in numbers relevant for clinical trials. (EV)

Contents

EUROPEAN COUNCIL
EXTERNAL ACTION
SECTORAL POLICIES
Russian invasion of Ukraine
FUNDAMENTAL RIGHTS - SOCIETAL ISSUES
EUROPEAN PARLIAMENT PLENARY
NEWS BRIEFS